| 1 | English French Notes Complete/Exclude
|
|---|
| 2 | 24. REGIONAL NODES EXAMINED.........:
|
|---|
| 3 | 25. REGIONAL NODES POSITIVE.........:
|
|---|
| 4 | 26. EXTRANODAL EXTENSION............:
|
|---|
| 5 | SATELLITE NODULES OF SKIN OR SUBCUTANEOUS TISSUE
|
|---|
| 6 | 28. NUMBER OF SATELLITE NODULES.....:
|
|---|
| 7 | 29. LOCATION OF IN-TRANSIT NODULES..:
|
|---|
| 8 | 31. CLARK'S LEVEL OF INVASION.......:
|
|---|
| 9 | 32. ANGIOLYMPHATIC INVASION.........:
|
|---|
| 10 | 33. PERINEURAL INVASION.............:
|
|---|
| 11 | 34. GENERAL SUMMARY STAGE...........:
|
|---|
| 12 | 35. AJCC CLINICAL STAGE (cTNM):
|
|---|
| 13 | AJCC STAGE.....................:
|
|---|
| 14 | 37. CLINICALLY AMELANOTIC...........:
|
|---|
| 15 | 38. AJCC PATHOLOGIC STAGE (pTNM):
|
|---|
| 16 | 39. STAGED BY:
|
|---|
| 17 | CLINICAL STAGE.................:
|
|---|
| 18 | PATHOLOGIC STAGE...............:
|
|---|
| 19 | 40. PROTOCOL ELIGIBILITY STATUS.....:
|
|---|
| 20 | 41. PROTOCOL PARTICIPATION..........:
|
|---|
| 21 | 42. DATE OF FIRST COURSE TREATMENT..:
|
|---|
| 22 | 43. DATE OF NON CA-DIRECTED SURGERY.:
|
|---|
| 23 | 44. NON CANCER-DIRECTED SURGERY.....:
|
|---|
| 24 | 45. TYPE OF BIOSPY..................:
|
|---|
| 25 | 46. DATE OF CANCER-DIRECTED SURGERY.:
|
|---|
| 26 | 47. SURGICAL APPROACH...............:
|
|---|
| 27 | 48. SURGERY OF PRIMARY SITE.........:
|
|---|
| 28 | 49. SURGICAL MARGINS................:
|
|---|
| 29 | 50. DISTANCE FROM TUMOR TO EDGE OF
|
|---|
| 30 | 51. SCOPE OF LYMPH NODE SURGERY.....:
|
|---|
| 31 | 52. NUMBER OF LYMPH NODES REMOVED...:
|
|---|
| 32 | 53. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
|
|---|
| 33 | OR DISTANT LYMPH NODE(S)........:
|
|---|
| 34 | 55. SURGICAL CLOSURE................:
|
|---|
| 35 | 56. REASON FOR NO SURGERY...........:
|
|---|
| 36 | 57. PRE-OP LYMPHOSCINTIGRAPHY.......:
|
|---|
| 37 | 58. SENTINEL NODES DETECTED BY......:
|
|---|
| 38 | 59. SENTINEL NODE BIOPSY............:
|
|---|
| 39 | 60. SENTINEL NODES EXAMINED.........:
|
|---|
| 40 | 61. SENTINEL NODES POSITIVE.........:
|
|---|
| 41 | 62. HOW WAS SENTINEL NODE
|
|---|
| 42 | PATHOLOGICALLY EXAMINED.........:
|
|---|
| 43 | 63. IF SENTINEL NODE(S) POSITIVE:
|
|---|
| 44 | WAS COMPLETE LYMPH NODE
|
|---|
| 45 | DISSECTION PERFORMED..........:
|
|---|
| 46 | NUMBER OF BASINS DETECTED.....:
|
|---|
| 47 | NUMBER OF BASINS POSITIVE.....:
|
|---|
| 48 | 64. DATE RADIATION STARTED..........:
|
|---|
| 49 | 65. RADIATION THERAPY...............:
|
|---|
| 50 | 66. REASON FOR NO RADIATION ........:
|
|---|
| 51 | 67. DATE CHEMOTHERAPY STARTED.......:
|
|---|
| 52 | 69. INTRAVENOUS THERAPY.............:
|
|---|
| 53 | 70. DATE HORMONE THERAPY STARTED....:
|
|---|
| 54 | 71. HORMONE THERAPY.................:
|
|---|
| 55 | IMMUNOTHERAPY THERAPY
|
|---|
| 56 | 72. DATE IMMUNOTHERAPY STARTED......:
|
|---|
| 57 | 74. IMMUNOTHERAPEUTIC AGENTS ADMINISTERED:
|
|---|
| 58 | VACCINE THERAPY................:
|
|---|
| 59 | GENE THERAPY...................:
|
|---|
| 60 | COLONY STIMULATING FACTORS.....:
|
|---|
| 61 | OTHER GIVEN, TYPE UNKNOWN......:
|
|---|
| 62 | OTHER THERAPY
|
|---|
| 63 | 75. DATE OTHER TREATMENT STARTED....:
|
|---|
| 64 | 76. OTHER TREATMENT.................:
|
|---|
| 65 | 77. DATE OF FIRST RECURRENCE........:
|
|---|
| 66 | 78. TYPE OF FIRST RECURRENCE........:
|
|---|
| 67 | 79. OTHER TYPE OF FIRST RECURRENCE..:
|
|---|
| 68 | 80. DATE OF LAST CONTACT OR DEATH...:
|
|---|
| 69 | 81. VITAL STATUS....................:
|
|---|
| 70 | 82. CANCER STATUS...................:
|
|---|
| 71 | TABLE VII - OTHER INFORMATION
|
|---|
| 72 | 83. COMPLETED BY....................:
|
|---|
| 73 | 84. REVIEWED BY CANCER COMMITTEE....:
|
|---|
| 74 | The BEHAVIOR code is not 3 (malignant).
|
|---|
| 75 | 8:Print Non-Hodgkin's Lymphoma PCE
|
|---|
| 76 | Patient Care Evaluation Study of Non-Hodgkin's Lymphoma
|
|---|
| 77 | AGE AT DIAGNOSIS
|
|---|
| 78 | PERSONAL HISTORY OF ANY CANCER
|
|---|
| 79 | PRE-EXISTING CONDITIONS
|
|---|
| 80 | PREVIOUS CHEMOTHERAPY/RADIATION THERAPY
|
|---|
| 81 | AIDS RISK CATEGORY
|
|---|
| 82 | AIDS RISK CATEGOR
|
|---|
| 83 | AGE AT DIAGNOSIS.....................:
|
|---|
| 84 | 313 OTHER CANCER.......................
|
|---|
| 85 | PERSONAL HISTORY OF ANY CANCER:
|
|---|
| 86 | 803 1ST PRIMARY SITE...................
|
|---|
| 87 | 803 1ST PRIMARY SITE...................//
|
|---|
| 88 | 804 1ST PRIMARY HISTOLOGY..............
|
|---|
| 89 | 804 1ST PRIMARY HISTOLOGY..............//
|
|---|
| 90 | 805 2ND PRIMARY SITE...................
|
|---|
| 91 | 805 2ND PRIMARY SITE...................//
|
|---|
| 92 | 806 2ND PRIMARY HISTOLOGY..............
|
|---|
| 93 | 806 2ND PRIMARY HISTOLOGY..............//
|
|---|
| 94 | PRE-EXISTING CONDITIONS:
|
|---|
| 95 | 807 ORGAN TRANSPLANT...................
|
|---|
| 96 | 808 HIV POSITIVE.......................
|
|---|
| 97 | 809 CROHN'S DISEASE/ULCERATIVE COLITIS.
|
|---|
| 98 | 811 SYSTEMIC LUPUS ERYTHEMATOSUS.......
|
|---|
| 99 | 812 RHEUMATOID ARTHRITIS/SJOGREN'S SYN.
|
|---|
| 100 | 813 PNEUMOCYSTIS CARINII...............
|
|---|
| 101 | 814 CMV INFECTION......................
|
|---|
| 102 | 816 MYCOBACTERIUM AVIUM................
|
|---|
| 103 | 817 OTHER PARASITIC INFECTIONS.........
|
|---|
| 104 | 818 OTHER CONGENTIAL DISEASES..........
|
|---|
| 105 | 819 OPPORTUNISTIC DISEASE (W/I 2 YEARS)
|
|---|
| 106 | PREVIOUS CHEMOTHERAPY/RADIATION THERAPY:
|
|---|
| 107 | 821 RADIATION THERAPY..................
|
|---|
| 108 | 822AIDS RISK CATEGORY...................
|
|---|
| 109 | DIAGNOSTIC WORKUP
|
|---|
| 110 | RESULTS OF LABORATORY TESTS
|
|---|
| 111 | ADDITIONAL TESTS
|
|---|
| 112 | REVIEW OF PATHOLOGY/OTH INST
|
|---|
| 113 | DIAGNOSTIC BIOPSIES
|
|---|
| 114 | SYSTEMIC SYMPTOMS
|
|---|
| 115 | DIAGNOSTIC TEST SPECIFICALLY RELATED TO HIV DISEASE
|
|---|
| 116 | HIV VIRAL LOADS
|
|---|
| 117 | SPECIFIC HISTOLOGIC INFORMATION
|
|---|
| 118 | CELL TYPE OF LYMPHOMA
|
|---|
| 119 | PATIENT STATUS AT DIAGNOSIS
|
|---|
| 120 | CLASS OF CLASS..............:
|
|---|
| 121 | 26DIAGNOSTIC CONFIRMATION.....
|
|---|
| 122 | DIAGNOSTIC WORKUP:
|
|---|
| 123 | 823 CT SCAN OF BRAIN..........
|
|---|
| 124 | 506 CT SCAN OF CHEST..........
|
|---|
| 125 | 824 CT SCAN OF ABDOMEN/PELVIS.
|
|---|
| 126 | 825 MRI OF BRAIN..............
|
|---|
| 127 | 826 MRI OF CHEST..............
|
|---|
| 128 | 827 MRI OF ABDOMEN/PELVIS.....
|
|---|
| 129 | 504 BONE SCAN.................
|
|---|
| 130 | 828 GALLIUM SCAN..............
|
|---|
| 131 | 829 PET SCAN..................
|
|---|
| 132 | 830 LUMBAR PUNCTURE...........
|
|---|
| 133 | RESULTS OF LABORATORY TESTS:
|
|---|
| 134 | 832 WHITE COUNT...............
|
|---|
| 135 | 833 PLATELET COUNT............
|
|---|
| 136 | 834 LACTIC DEHYDROGENASE (LDH)
|
|---|
| 137 | 835 LIVER FUNCTION STUDIES....
|
|---|
| 138 | 836 TOTAL PROTEIN/ALBUMIN.....
|
|---|
| 139 | ADDITIONAL TESTS:
|
|---|
| 140 | 516 TUMOR SURFACE MARKER......
|
|---|
| 141 | 514 CYTOGENETIC TESTING.......
|
|---|
| 142 | 837 GENE REARRANGEMENTS.......
|
|---|
| 143 | 838REVIEW OF PATHOLOGY/OTH INST
|
|---|
| 144 | DIAGNOSTIC BIOPSIES:
|
|---|
| 145 | 839 LYMPH NODE................
|
|---|
| 146 | 840 BONE MARROW...............
|
|---|
| 147 | 841 CSF CYTOLOGY..............
|
|---|
| 148 | 842 OTHER SITE................
|
|---|
| 149 | 843SYSTEMIC SYMPTOMS...........
|
|---|
| 150 | DIAGNOSTIC TESTS SPECIFICALLY RELATED TO HIV DISEASE:
|
|---|
| 151 | 845 HIV VIRAL LOADS...........
|
|---|
| 152 | DATE OF INITIAL DIAGNOSIS...:
|
|---|
| 153 | PRIMARY SITE................:
|
|---|
| 154 | HISTOLOGY/BEHAVIOR CODE.....:
|
|---|
| 155 | 846SPECIFIC HISTOLOGIC INFO....
|
|---|
| 156 | 847CELL TYPE OF LYMPHOMA.......
|
|---|
| 157 | 848PATIENT STATUS AT DIAGNOSIS.
|
|---|
| 158 | AJCC CLINICAL STAGE GROUP
|
|---|
| 159 | CLINICALLY STAGED BY
|
|---|
| 160 | AJCC PATHOLOGIC STAGE GROUP
|
|---|
| 161 | PATHOLOGICALLY STAGED BY
|
|---|
| 162 | TYPE OF STAGING SYSTEM (PEDIATRIC)
|
|---|
| 163 | PEDIATRIC STAGE
|
|---|
| 164 | STAGED BY (PEDIATRIC STAGE)
|
|---|
| 165 | EXTRANODAL SITES
|
|---|
| 166 | AJCC CLINICAL STAGE GROUP......:
|
|---|
| 167 | 19CLINICALLY STAGED BY...........
|
|---|
| 168 | AJCC PATHOLOGIC STAGE GROUP ...:
|
|---|
| 169 | 89PATHOLOGICALLY STAGED BY.......
|
|---|
| 170 | 849TYPE OF STAGING SYS (PEDIATRIC)
|
|---|
| 171 | 850PEDIATRIC STAGE................
|
|---|
| 172 | 851STAGED BY (PEDIATRIC STAGE)....
|
|---|
| 173 | EXTRANODAL SITES:
|
|---|
| 174 | 852 EXTRANODAL SITE 1............
|
|---|
| 175 | 853 EXTRANODAL SITE 2............
|
|---|
| 176 | 854 EXTRANODAL SITE 3............
|
|---|
| 177 | DATE OF FIRST COURSE OF TREATMENT
|
|---|
| 178 | SYSTEMIC CHEMOTHERAPY
|
|---|
| 179 | INTRATHECAL CHEMOTHERAPY
|
|---|
| 180 | DATE OF FIRST COURSE OF TREATMENT.:
|
|---|
| 181 | EXTRANODAL SURGERY SITE.........: None
|
|---|
| 182 | EXTRANODAL SURGICAL PROCEDURE...: 00 No additional surgical procedures
|
|---|
| 183 | 855 EXTRANODAL SURGERY SITE.........
|
|---|
| 184 | 856 EXTRANODAL SURGICAL PROCEDURE...
|
|---|
| 185 | RADIATION DATE..................:
|
|---|
| 186 | IRRADIATED FIELDS:
|
|---|
| 187 | LYMPH NODES ABOVE DIAPHRAGM...: Not irradiated
|
|---|
| 188 | LYMPH NODES BELOW DIAPHRAGM...: Not irradiated
|
|---|
| 189 | BRAIN.........................: Not irradiated
|
|---|
| 190 | OTHER EXTRANODAL SITE(S)......: Not irradiated
|
|---|
| 191 | TOTAL BODY....................: Not irradiated
|
|---|
| 192 | RADIATION/CHEMOTHERAPY SEQUENCE.: NA, no radiation and/or no chemo given
|
|---|
| 193 | LYMPH NODES ABOVE DIAPHRAGM...: NA, unknown if radiation therapy given
|
|---|
| 194 | LYMPH NODES BELOW DIAPHRAGM...: NA, unknown if radiation therapy given
|
|---|
| 195 | BRAIN.........................: NA, unknown if radiation therapy given
|
|---|
| 196 | OTHER EXTRANODAL SITE(S)......: NA, unknown if radiation therapy given
|
|---|
| 197 | TOTAL BODY....................: NA, unknown if radiation therapy given
|
|---|
| 198 | RADIATION/CHEMOTHERAPY SEQUENCE.: Unknown if radiation and/or chemo given
|
|---|
| 199 | 857 LYMPH NODES ABOVE DIAPHRAGM...
|
|---|
| 200 | 858 LYMPH NODES BELOW DIAPHRAGM...
|
|---|
| 201 | 860 OTHER EXTRANODAL SITE(S)......
|
|---|
| 202 | 861 TOTAL BODY....................
|
|---|
| 203 | 862 RADIATION/CHEMOTHERAPY SEQUENCE.
|
|---|
| 204 | 864 SYSTEMIC CHEMOTHERAPY...........
|
|---|
| 205 | SYSTEMIC CHEMOTHERAPY DATE......: 00/00/0000
|
|---|
| 206 | NUMBER OF PLANNED CYCLES........: NA
|
|---|
| 207 | AGENT ADMINISTERED DURING SYSTEMIC CHEMOTHERAPY:
|
|---|
| 208 | SINGLE-AGENT CHEMOTHERAPY:
|
|---|
| 209 | CHLORAMBUCIL.....: NA DOXORUBICIN......: NA
|
|---|
| 210 | CYCLOPHOSPHAMIDE.: NA FLUDARABINE......: NA
|
|---|
| 211 | COMBINATION CHEMOTHERAPY:
|
|---|
| 212 | CVP..............: NA PRO-MACE-Cyta BOM: NA
|
|---|
| 213 | COMLA............: NA OTHER............: NA
|
|---|
| 214 | HIGH DOSE W STEM CELL RESCUE..: No
|
|---|
| 215 | NUMBER OF PLANNED CYCLES........: Unknown if chemotherapy given
|
|---|
| 216 | CHLORAMBUCIL.....: Unknown if given DOXORUBICIN......: Unknown if given
|
|---|
| 217 | CYCLOPHOSPHAMIDE.: Unknown if given FLUDARABINE......: Unknown if given
|
|---|
| 218 | CHOP.............: Unknown if given M-BACOD..........: Unknown if given
|
|---|
| 219 | CVP..............: Unknown if given PRO-MACE-Cyta BOM: Unknown if given
|
|---|
| 220 | COMLA............: Unknown if given OTHER............: Unknown if given
|
|---|
| 221 | MACOP-B..........: Unknown if given
|
|---|
| 222 | HIGH DOSE W STEM CELL RESCUE..: Unknown if given
|
|---|
| 223 | 865 SYSTEMIC CHEMOTHERAPY DATE......
|
|---|
| 224 | 866 NUMBER OF PLANNED CYCLES........
|
|---|
| 225 | 876 PRO-MACE-Cyta BOM...........
|
|---|
| 226 | 878 HIGH DOSE W STEM CELL RESCUE....
|
|---|
| 227 | 879 INTRATHECAL CHEMOTHERAPY........
|
|---|
| 228 | PURPOSE.........................: NA, not administered
|
|---|
| 229 | PURPOSE.........................: Unknown if administered
|
|---|
| 230 | 883 MONOCLONAL ANTIBODIES...........
|
|---|
| 231 | 884 VACCINE THERAPY.................
|
|---|
| 232 | OTHER TYPE OF FIRST RECURRENCE
|
|---|
| 233 | 71.4OTHER TYPE OF FIRST RECURRENCE
|
|---|
| 234 | 1. INSTITUTION ID NUMBER...........: H6
|
|---|
| 235 | 6. AGE AT DIAGNOSIS................:
|
|---|
| 236 | 8. SPANISH ORIGIN..................:
|
|---|
| 237 | 10. PRIMARY PAYER AT DIAGNOSIS......:
|
|---|
| 238 | 11. FAMILY HISTORY OF CANCER:
|
|---|
| 239 | OTHER CANCER..................:
|
|---|
| 240 | 12. PERSONAL HISTORY OF ANY CANCER:
|
|---|
| 241 | 1ST PRIMARY SITE..............:
|
|---|
| 242 | 1ST PRIMARY HISTOLOGY.........:
|
|---|
| 243 | 2ND PRIMARY SITE..............:
|
|---|
| 244 | 2ND PRIMARY HISTOLOGY.........:
|
|---|
| 245 | 13. PRE-EXISTING CONDITIONS:
|
|---|
| 246 | ORGAN TRANSPLANT..............:
|
|---|
| 247 | HIV POSITIVE..................:
|
|---|
| 248 | CROHN'S DIS/ULCERATIVE COLITIS:
|
|---|
| 249 | SYSTEMIC LUPUS ERYTHEMATOSUS..:
|
|---|
| 250 | RHEUMATOID ARTHRITIS/SJOGREN'S:
|
|---|
| 251 | PNEUMOCYSTIS CARINII..........:
|
|---|
| 252 | CMV INFECTION.................:
|
|---|
| 253 | MYCOBACTERIUM AVIUM...........:
|
|---|
| 254 | OTHER PARASITIC INFECTIONS....:
|
|---|
| 255 | OTHER CONGENITAL DISEASES.....:
|
|---|
| 256 | OPPORTUNISTIC DISEASE.........:
|
|---|
| 257 | 14. PREVIOUS CHEMOTHERAPY/RADIATION THERAPY:
|
|---|
| 258 | RADIATION THERAPY.............:
|
|---|
| 259 | 15. AIDS RISK CATEGORY..............:
|
|---|
| 260 | Print Non-Hodgkin's Lymphoma PCE
|
|---|
| 261 | PCE Study of Non-Hodgkin's Lymphoma
|
|---|
| 262 | 16. CLASS OF CASE...................:
|
|---|
| 263 | 17. DIAGNOSTIC CONFIRMATION.........:
|
|---|
| 264 | 18. DIAGNOSTIC WORKUP:
|
|---|
| 265 | CT SCAN OF BRAIN..............:
|
|---|
| 266 | CT SCAN OF CHEST..............:
|
|---|
| 267 | CT SCAN OF ABDOMEN/PELVIS.....:
|
|---|
| 268 | MRI OF BRAIN..................:
|
|---|
| 269 | MRI OF CHEST..................:
|
|---|
| 270 | MRI OF ABDOMEN/PELVIS.........:
|
|---|
| 271 | BONE SCAN.....................:
|
|---|
| 272 | GALLIUM SCAN..................:
|
|---|
| 273 | PET SCAN......................:
|
|---|
| 274 | LUMBAR PUNCTURE...............:
|
|---|
| 275 | 19. RESULTS OF LABORATORY TESTS:
|
|---|
| 276 | WHITE COUNT...................:
|
|---|
| 277 | PLATELET COUNT................:
|
|---|
| 278 | LACTIC DEHYDROGENASE (LDH)....:
|
|---|
| 279 | LIVER FUNCTION STUDIES........:
|
|---|
| 280 | TOTAL PROTEIN/ALBUMIN.........:
|
|---|
| 281 | 20. ADDITIONAL TESTS:
|
|---|
| 282 | TUMOR SURFACE MARKER..........:
|
|---|
| 283 | CYTOGENETIC TESTING...........:
|
|---|
| 284 | GENE REARRANGEMENTS...........:
|
|---|
| 285 | 21. REVIEW OF PATHOLOGY/OTH INST....:
|
|---|
| 286 | 22. DIAGNOSTIC BIOPSIES:
|
|---|
| 287 | LYMPH NODE....................:
|
|---|
| 288 | BONE MARROW...................:
|
|---|
| 289 | CSF CYTOLOGY..................:
|
|---|
| 290 | OTHER SITE....................:
|
|---|
| 291 | 23. SYSTEMIC SYSTEMS................:
|
|---|
| 292 | 24. DIAGNOSTIC TESTS SPECIFICALLY RELATED TO HIV DISEASE:
|
|---|
| 293 | HIV VIRAL LOADS...............:
|
|---|
| 294 | 25. DATE OF INITIAL DIAGNOSIS.......:
|
|---|
| 295 | 26. PRIMARY SITE....................:
|
|---|
| 296 | 27. HISTOLOGY/29. BEHAVIOR CODE.....:
|
|---|
| 297 | 28. SPECIFIC HISTOLOGIC INFO........:
|
|---|
| 298 | 30. CELL TYPE OF LYMPHOMA...........:
|
|---|
| 299 | 31. PATIENT STATUS OF DIAGNOSIS.....:
|
|---|
| 300 | 32. AJCC CLINICAL STAGE GROUP.......:
|
|---|
| 301 | 33. CLINICALLY STAGED BY............:
|
|---|
| 302 | 34. AJCC PATHOLOGIC STAGE GROUP.....:
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
